Supplementary Material – PD-1 Targeted Immunotherapy For Advanced Hepatocellular Cancer: Current Utilization And Outcomes In The United States

Supplementary Material. PD-1 Targeted Immunotherapy For Advanced Hepatocellular Cancer: Current Utilization And Outcomes In The United States Supplemental Table 1: ICD 09 and ICD 10 codes used for abstraction of patient comorbidities. Supplemental Table 2: comorbidities of included patients. Supplemental Figure 1: proportion of advanced HCC receiving PD-1 IMT according to US geography. Supplemental Figure 2: interaction analyses showing treatment effectiveness of PD-1 IMT versus no PD-1 IMT across patient subgroups. P-values were adjusted for multiplicity using the Bonferroni correction.